Andrew, N.Kearney, D.Selva-Nayagam, D.2013-09-062013-09-062013Eye, 2013; 27(4):561-5630950-222X1476-5454http://hdl.handle.net/2440/79796PURPOSE The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD Retrospective, single-centre, interventional case series. RESULTS Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.en© 2013 Macmillan Publishers Limited All rights reservedreactive lymphoid hyperplasialymphoproliferative disorderscorticosteroiddrug therapyorbital diseaseJournal article002012811610.1038/eye.2012.2880003175940000152-s2.0-8487611304919696Selva-Nayagam, D. [0000-0002-2169-5417]